Potent benzoazepinone γ-secretase modulators with improved bioavailability.

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-beta (Aβ) plaque accumulation.
• γ-secretase modulators (GSMs) are a therapeutic strategy for AD, aiming to reduce Aβ42 production.
• Cinnamyl amides have advanced to clinical trials, but alternatives are sought to optimize drug properties.

Purpose of the Study:

• To develop novel triazolyl amide γ-secretase modulators as potential Alzheimer's disease therapeutics.
• To explore imidazomethoxyarene moiety modifications for improved pharmacokinetic (PK) and safety profiles.
• To evaluate the efficacy of these novel compounds in reducing brain Aβ42 levels.

Main Methods:

• Synthesis and chemical modification of benzoazepinone-based triazolyl amides.
• In vitro assessment of γ-secretase modulation activity.
• In vivo pharmacokinetic studies in preclinical models (e.g., dog, mouse, rat).
• Measurement of brain Aβ42 levels in transgenic mouse and rat models of Alzheimer's disease.

Main Results:

• Triazolyl amide compounds demonstrated potent γ-secretase modulation, serving as effective alternatives to cinnamyl amides.
• Imidazomethoxyarene modifications successfully fine-tuned physical properties and addressed hERG binding.
• Significant improvements in half-life and bioavailability were observed, particularly in canine models.
• Sustained reduction in brain Aβ42 levels was confirmed in both transgenic mouse and rat models.

Conclusions:

• Novel triazolyl amide γ-secretase modulators represent a promising therapeutic avenue for Alzheimer's disease.
• These compounds offer improved pharmacokinetic profiles and safety compared to earlier generations.
• The developed compounds effectively lower brain Aβ42, supporting their potential for clinical translation in Alzheimer's disease treatment.